Breakpoints cover image

#68 – IDWeek 2022 Recap: Late Breaking Trials and Pipeline Antibacterials

Breakpoints

00:00

HIV AIDS - Is the Nader CD4 Cell Count What Matters?

Everybody in the trial, including those in the original deferred group were offered ART to start by January 1, 2016. They retained 4,436 patients in this additional analysis post 2016. The remaining excess risk was primarily driven by patients that were 35 years of age or less. So it's definitely got me thinking. There still is probably going to spark a lot of research moving forward.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
 Get the app